Adamis Pharmaceuticals Corporation ADMP
0.78 0.00 (+0.00%)
Sep 7, 2023, 3:59 PM EDT
0.75 Day range 0.7899
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) —
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy0
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 1
- 2 months ago 1
- 3 months ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | -0.08 | 0.0% | 1.51M | +2.8% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | -0.06 | 0.0% | 2.15M | +85.6% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 4.76M | -43.6% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 9.20M | +93.4% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2020 | Maxim Group | Upgrade | Hold | Buy |
| Nov 26, 2019 | Raymond James | Downgrade | Outperform | Market Perform |
| Nov 25, 2019 | Maxim Group | Downgrade | Buy | Hold |
| Jul 23, 2019 | B. Riley FBR | Upgrade | Sell | Neutral |
| Jul 16, 2019 | B. Riley | Downgrade | Neutral | Sell |
| Nov 12, 2018 | B. Riley FBR | Downgrade | Buy | Neutral |
| May 14, 2018 | Maxim Group | Maintained | Buy | Buy |
| May 5, 2018 | B. Riley FBR | Maintained | Buy | Buy |
| May 5, 2018 | B. Riley FBR | Initiated | — | Buy |
| Apr 23, 2018 | H.C. Wainwright | Initiated | — | Buy |
| Sep 13, 2017 | Raymond James | Initiated | — | Outperform |
| Nov 30, 2015 | Maxim Group | Initiated | — | Buy |
| May 29, 2015 | Mizuho | Initiated | — | Buy |